Mark Bodmer is the Chief Executive Officer at Nucleome Therapeutics, a biotechnology company that utilizes 3D genomics to discover precision medicines.
Mark Bodmer is the Chief Executive Officer at Nucleome Therapeutics, a biotechnology company that utilizes 3D genomics to discover precision medicines for complex diseases. He joined the company from Evelo Biosciences, where he served as Chief Scientific Officer and President of R&D since 2016. Bodmer holds a PhD in Genetics from the University of Cambridge.
Full founder directory · Investor directory · Company funding database · Fundraising library
The Startup Fundraising Platform
Raise funds for your startup
Find the right investors and get real replies — instantly, powered by AI.
Takes 30 seconds · No credit card · Cancel anytime
Slide-by-slide guide